Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper ...

New findings about semaglutide and tirzepatide use from health records suggest lower overall weight loss but also factors that predict success.

In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of treatment Tirzepatide users experienced greater waistline reduction (7. ...

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically meaningful weight loss and improved glycemic control.

Trials are also underway to test whether tirzepatide reduces the risk of heart attacks and strokes, as semaglutide has already been shown to do. A Stronger Path to Health ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised by the drugs' clinical trials, a new study says.

Encouraging phase 2 results of tirzepatide in the resolution of MASH and improvement in fibrosis support further investigation into the GIP–GLP-1 receptor agonist for liver disease.

People who take weight-loss drugs hoping to achieve the impressive results observed in large clinical trials may need to adjust their expectations, a new study suggests.

In real-world cohort, percentage weight reduction at 1 year was 3.6%, 6.8%, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.